Garderet, Laurent
Laubach, Jacob P.
Stoppa, Anne-Marie
Hari, Parameswaran
Cavo, Michele
Ludwig, Heinz
Mateos, MarĂa-Victoria
Luptakova, Katarina
Lin, Jianchang
Yung, Godwin
van de Velde, Helgi
Berg, Deborah
Moreau, Philippe
Richardson, Paul G.
Article History
Received: 15 September 2017
Revised: 14 November 2017
Accepted: 23 November 2017
First Online: 12 March 2018
Compliance with ethical standards
:
: LG reports personal fees from Amgen, Takeda, and Novartis; JPL has received research funding from Onyx, Takeda, Celgene, and Novartis, and personal fees from Takeda, Celgene, and Novartis; A-MS has received personal fees and non-financial support from Celgene and Takeda; PH has received research funding and personal fees from Takeda; MC has received personal fees from Janssen-Cilag, Celgene, Millennium Pharmaceuticals Inc., Amgen, and Bristol-Myers Squibb; HL has received research funding from Amgen and Takeda, and personal fees from Amgen, Takeda, Bristol-Myers Squibb, Celgene, and Janssen; M-VM reports personal fees from Janssen, Celgene, Amgen, and Bristol-Myers Squibb; HVdV, JL, GY, and DB are employees of Millennium Pharmaceuticals Inc.; KL was an employee of Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited at the time of the study and during manuscript development; PM reports third-party funding from Millennium Pharmaceuticals Inc. and Celgene, and received personal fees from Bristol-Myers Squibb, Janssen, and Novartis; PGR has received funding for advisory boards from Celgene, Novartis, and Millennium Pharmaceuticals Inc.